Newly-formed Archerfish Precision Diagnostics Pte Ltd: Ushers a New Era in Advanced Diagnostics

We are proud to share that Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories have merged to form Archerfish Precision Diagnostics, marking a major milestone for Singapore’s clinical diagnostics sector. This merger brings together deep expertise in molecular diagnostics, serology, and AI-driven technologies — and is supported by a strategic consortium including Temasek Life Sciences Laboratory, Temasek Life Sciences Accelerator, The Life Sciences Innovation Fund, and SEEDS Capital.

The new entity, Archerfish, aims to advance precision medicine and early disease detection, with an emphasis on conditions prevalent in Asia such as cancer and infectious diseases. By combining Next-Generation Sequencing (NGS), serum proteomics, and artificial intelligence, Archerfish will deliver accurate, data-driven diagnostics to both public and private healthcare sectors.

With strong leadership and a shared vision to transform diagnostic science, Archerfish is well-positioned to scale innovation, enhance patient outcomes, and contribute meaningfully to the region’s healthcare ecosystem.

You may read more here!